Indirubin-3'-monoxime (Synonyms: Indirubin-3'-oxime)

Name: Indirubin-3'-monoxime
Brand: MedChemExpress
SKU: HY-19807
Rating: 5.0 (3 reviews)

Cat. No.: HY-19807 Purity: 99.76%: FAQs
Data Sheet
SDS

COA
Handling Instructions Technical Support

Indirubin-3'-monoxime is a potent GSK-3β inhibitor, and weakly inhibits 5-Lipoxygenase, with IC₅₀s of 22 nM and 7.8-10 µM, respectively; Indirubin-3'-monoxime also shows inhibitory activities against CDK5/p25 and CDK1/cyclin B, with IC₅₀s of 100 and 180 nM.

For research use only. We do not sell to patients.

Indirubin-3'-monoxime Chemical Structure

CAS No. : 160807-49-8

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	Get quote
200 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Indirubin-3'-monoxime:

Indirubin In-stock

3 Publications Citing Use of MCE Indirubin-3'-monoxime

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All GSK-3 Isoform Specific Products:

View All Isoforms

GSK-3 GSK-3α GSK-3β

View All CDK Isoform Specific Products:

View All Isoforms

CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK11 CDK12 CDK13 CDK14 CDK16 CDK19 CDC CLK Pho85

View All Lipoxygenase Isoform Specific Products:

View All Isoforms

5-LOX 12-LOX 15-LOX

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]^[3]

GSK-3β

22 nM (IC₅₀)

CDK5/p25

100 nM (IC₅₀)

CDK1/cyclin B

180 nM (IC₅₀)

5-LOX

7.8-10 μM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	62 μM Compound: Indirubin-3'-monoxime	Inhibitory activity on the proliferation of Human lung carcinoma A549 cancer cells using MTT or sulforhodamine B assay Inhibitory activity on the proliferation of Human lung carcinoma A549 cancer cells using MTT or sulforhodamine B assay	[PMID: 15993584]
Cancer cell lines	IC₅₀	> 100 μM Compound: Indirubin-3'-monoxime	Inhibitory activity on the proliferation of Human colon carcinoma Co12 cancer cells using MTT or sulforhodamine B assay Inhibitory activity on the proliferation of Human colon carcinoma Co12 cancer cells using MTT or sulforhodamine B assay	[PMID: 15993584]
HCT-116	IC₅₀	12 μM Compound: 16	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 19783149]
Hep 3B2	IC₅₀	9 μM Compound: Indirubin-3'-oxime	Growth inhibition of human Hep3B cells after 72 hrs by MTS/PMS system based colorimetric assay Growth inhibition of human Hep3B cells after 72 hrs by MTS/PMS system based colorimetric assay	[PMID: 25988923]
HL-60	IC₅₀	> 100 μM Compound: Indirubin-3'-monoxime	Inhibitory activity on the proliferation of Human myeloid leukemia HL-60 cancer cells using MTT or sulforhodamine B assay Inhibitory activity on the proliferation of Human myeloid leukemia HL-60 cancer cells using MTT or sulforhodamine B assay	[PMID: 15993584]
HL-60	IC₅₀	15.7 μM Compound: 16	Antiproliferative activity against human HL60 cells after 5 days by MTT assay Antiproliferative activity against human HL60 cells after 5 days by MTT assay	[PMID: 19783149]
HT-1080	IC₅₀	4.8 μM Compound: Indirubin-3'-monoxime	Inhibitory activity on the proliferation of Human fibrosarcoma HT1080 cancer cells using MTT or sulforhodamine B assay Inhibitory activity on the proliferation of Human fibrosarcoma HT1080 cancer cells using MTT or sulforhodamine B assay	[PMID: 15993584]
IMR-90	IC₅₀	18.2 μM Compound: 16	Antiproliferative activity against human IMR90 cells after 72 hrs by MTT assay Antiproliferative activity against human IMR90 cells after 72 hrs by MTT assay	[PMID: 19783149]
K562	IC₅₀	> 30 μM Compound: 16	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 19783149]
KB	IC₅₀	19.2 μM Compound: Indirubin-3'-oxime	Growth inhibition of human KB cells after 72 hrs by MTS/PMS system based colorimetric assay Growth inhibition of human KB cells after 72 hrs by MTS/PMS system based colorimetric assay	[PMID: 25988923]
MCF7	IC₅₀	25.5 μM Compound: Indirubin-3'-oxime	Growth inhibition of human MCF7 cells after 72 hrs by MTS/PMS system based colorimetric assay Growth inhibition of human MCF7 cells after 72 hrs by MTS/PMS system based colorimetric assay	[PMID: 25988923]
MKN-45	IC₅₀	36.7 μM Compound: Indirubin-3'-oxime	Growth inhibition of human MKN45 cells after 72 hrs by MTS/PMS system based colorimetric assay Growth inhibition of human MKN45 cells after 72 hrs by MTS/PMS system based colorimetric assay	[PMID: 25988923]
MV4-11	IC₅₀	0.15 μM Compound: 10	Antiproliferative activity against wild type FLT3 expressing human MV411 cells after 72 hrs by WST8 assay Antiproliferative activity against wild type FLT3 expressing human MV411 cells after 72 hrs by WST8 assay	[PMID: 20153646]
NCI-H460	IC₅₀	32.6 μM Compound: Indirubin-3'-oxime	Growth inhibition of human NCI-H460 cells after 72 hrs by MTS/PMS system based colorimetric assay Growth inhibition of human NCI-H460 cells after 72 hrs by MTS/PMS system based colorimetric assay	[PMID: 25988923]
RS4-11	IC₅₀	3.56 μM Compound: 10	Antiproliferative activity against human RS4:11 cells having FLT3-ITD mutation after 72 hrs by WST8 assay Antiproliferative activity against human RS4:11 cells having FLT3-ITD mutation after 72 hrs by WST8 assay	[PMID: 20153646]
SF-268	IC₅₀	37 μM Compound: Indirubin-3'-oxime	Growth inhibition of human SF268 cells after 72 hrs by MTS/PMS system based colorimetric assay Growth inhibition of human SF268 cells after 72 hrs by MTS/PMS system based colorimetric assay	[PMID: 25988923]
SH-SY5Y	IC₅₀	> 25 μM Compound: 7a	Survival of human SH-SY5Y cells after 24 hrs by MTS reduction assay Survival of human SH-SY5Y cells after 24 hrs by MTS reduction assay	[PMID: 16854069]
SH-SY5Y	IC₅₀	> 25 μM Compound: 7a	Death of human SH-SY5Y cells in presence of 20 uM Q-VD-OPh by MTS reduction assay Death of human SH-SY5Y cells in presence of 20 uM Q-VD-OPh by MTS reduction assay	[PMID: 16854069]
SH-SY5Y	IC₅₀	12 μM Compound: 7a	Survival of human SH-SY5Y cells after 48 hrs by MTS reduction assay Survival of human SH-SY5Y cells after 48 hrs by MTS reduction assay	[PMID: 16854069]
SH-SY5Y	IC₅₀	13 μM Compound: 7a	Death of human SH-SY5Y cells in absence of 20 uM Q-VD-OPh by MTS reduction assay Death of human SH-SY5Y cells in absence of 20 uM Q-VD-OPh by MTS reduction assay	[PMID: 16854069]
T-cell	IC₅₀	< 20 μM Compound: 13, 13M	Inhibition of JAK-mediated IL6-induced Stat1 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry Inhibition of JAK-mediated IL6-induced Stat1 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry	[PMID: 18157122]
T-cell	IC₅₀	< 20 μM Compound: 13, 13M	Inhibition of JAK-mediated IL10-induced Stat3 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry Inhibition of JAK-mediated IL10-induced Stat3 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry	[PMID: 18157122]
T-cell	IC₅₀	< 20 μM Compound: 13, 13M	Inhibition of JAK-mediated interferon-gamma-induced Stat1 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry Inhibition of JAK-mediated interferon-gamma-induced Stat1 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry	[PMID: 18157122]
T-cell	IC₅₀	< 20 μM Compound: 13, 13M	Inhibition of JAK-mediated IL6-induced Stat3 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry Inhibition of JAK-mediated IL6-induced Stat3 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry	[PMID: 18157122]
T-cell	IC₅₀	< 20 μM Compound: 13, 13M	Inhibition of JAK-mediated IL15-induced Stat5 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry Inhibition of JAK-mediated IL15-induced Stat5 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry	[PMID: 18157122]
T-cell	IC₅₀	< 20 μM Compound: 13, 13M	Inhibition of JAK-mediated IL7-induced Stat5 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry Inhibition of JAK-mediated IL7-induced Stat5 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry	[PMID: 18157122]
T-cell	IC₅₀	< 20 μM Compound: 13, 13M	Inhibition of JAK-mediated IL4-induced Stat6 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry Inhibition of JAK-mediated IL4-induced Stat6 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry	[PMID: 18157122]
T-cell	IC₅₀	< 20 μM Compound: 13, 13M	Inhibition of JAK-mediated IL4-induced Stat5 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry Inhibition of JAK-mediated IL4-induced Stat5 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry	[PMID: 18157122]
T-cell	IC₅₀	< 20 μM Compound: 13, 13M	Inhibition of JAK-mediated IL6-induced Stat1 phosphorylation in BALB/c mouse CD8+ T cells by Phospho-Flow cytometry Inhibition of JAK-mediated IL6-induced Stat1 phosphorylation in BALB/c mouse CD8+ T cells by Phospho-Flow cytometry	[PMID: 18157122]
T-cell	IC₅₀	< 20 μM Compound: 13, 13M	Inhibition of JAK-mediated IL10-induced Stat3 phosphorylation in BALB/c mouse CD8+ T cells by Phospho-Flow cytometry Inhibition of JAK-mediated IL10-induced Stat3 phosphorylation in BALB/c mouse CD8+ T cells by Phospho-Flow cytometry	[PMID: 18157122]
T-cell	IC₅₀	< 20 μM Compound: 13, 13M	Inhibition of JAK-mediated IL6-induced Stat3 phosphorylation in BALB/c mouse CD8+ T cells by Phospho-Flow cytometry Inhibition of JAK-mediated IL6-induced Stat3 phosphorylation in BALB/c mouse CD8+ T cells by Phospho-Flow cytometry	[PMID: 18157122]
T-cell	IC₅₀	< 20 μM Compound: 13, 13M	Inhibition of JAK-mediated IL15-induced Stat5 phosphorylation in BALB/c mouse CD8+ T cells by Phospho-Flow cytometry Inhibition of JAK-mediated IL15-induced Stat5 phosphorylation in BALB/c mouse CD8+ T cells by Phospho-Flow cytometry	[PMID: 18157122]
T-cell	IC₅₀	< 20 μM Compound: 13, 13M	Inhibition of JAK-mediated IL7-induced Stat5 phosphorylation in BALB/c mouse CD8+ T cells by Phospho-Flow cytometry Inhibition of JAK-mediated IL7-induced Stat5 phosphorylation in BALB/c mouse CD8+ T cells by Phospho-Flow cytometry	[PMID: 18157122]
T-cell	IC₅₀	< 20 μM Compound: 13, 13M	Inhibition of JAK-mediated IL4-induced Stat6 phosphorylation in BALB/c mouse CD8+ T cells by Phospho-Flow cytometry Inhibition of JAK-mediated IL4-induced Stat6 phosphorylation in BALB/c mouse CD8+ T cells by Phospho-Flow cytometry	[PMID: 18157122]
T-cell	IC₅₀	< 20 μM Compound: 13, 13M	Inhibition of JAK-mediated IL4-induced Stat5 phosphorylation in BALB/c mouse CD8+ T cells by Phospho-Flow cytometry Inhibition of JAK-mediated IL4-induced Stat5 phosphorylation in BALB/c mouse CD8+ T cells by Phospho-Flow cytometry	[PMID: 18157122]

In Vitro

Indirubin-3'-monoxime inhibits GSK-3β by competing with ATP, with K_i of 0.85 μM, and K_m of 110 μM. Indirubin-3'-monoxime also inhibits tau phosphorylation by GSK-3β, with an IC₅₀ value of around 100 nM. Indirubin-3'-monoxime completely inhibits the phosphorylation of the AT100 epitope^[1]. Indirubin-3'-monoxime inhibits vascular smooth muscle cell (VSMC) proliferation with IC₅₀ of ～2 μM. Indirubin-3'-monoxime blunts migration of VSMC stimulated with the PDGF. Indirubin-3'-monoxime interferes with the migratory response in VSMC, and also suppresses the production of pro-migratory LT in monocytes. Moreover, Indirubin-3'-monoxime inhibits 5-lipoxygenase (5-LO) product synthesis in monocytes and neutrophils, with the same potency (IC₅₀=5.0±1.1 and 3.7±1.2 μM, respectively). Indirubin-3'-monoxime is an inhibitor of 5-LO, with IC₅₀ of 7.8-10 μM in cell-free assay^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Indirubin-3'-monoxime (0.1, 0.2 and 0.4 mg/kg, i.p) dose dependently reverses the cognitive impairment and combats the elevated oxidative stress markers in HFD fed mice. Indirubin-3'-monoxime also dose dependently lowers the serum glucose, TGs, TC and insulin levels, and improves the β-cell functioning in HFD fed mice. Moreover, Indirubin-3'-monoxime treatment significantly decreases HOMA-IR levels compared to HFD group. Indirubin-3'-monoxime (0.4 mg/kg) significantly attenuates the increased EL in the HFD group^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

277.28

Formula

C₁₆H₁₁N₃O₂

CAS No.

160807-49-8

Appearance

Solid

Color

Brown to red

SMILES

O=C1NC2=C(C=CC=C2)/C1=C3NC4=C(C=CC=C4)C\3=N/O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 125 mg/mL (450.81 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.6065 mL	18.0323 mL	36.0646 mL
5 mM	0.7213 mL	3.6065 mL	7.2129 mL
10 mM	0.3606 mL	1.8032 mL	3.6065 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.02 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.76%

Select Batch:

Data Sheet (288 KB) SDS (393 KB)

COA (258 KB) HNMR (264 KB) LCMS (93 KB)

Handling Instructions (2659 KB)

References

[1]. Leclerc S, et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem. 2001 Jan 5;276(1):251-60. [Content Brief]

[2]. Sharma S, et al. Neuroprotective role of Indirubin-3'-monoxime, a GSKβ inhibitor in high fat diet induced cognitive impairment in mice. Biochem Biophys Res Commun. 2014 Oct 3;452(4):1009-15. [Content Brief]

[3]. Blazevic T, et al. Indirubin-3'-monoxime exerts a dual mode of inhibition towards leukotriene-mediated vascular smooth muscle cell migration. Cardiovasc Res. 2014 Mar 1;101(3):522-32. [Content Brief]

[4]. Cao Z, et al. Indirubin Derivatives as Dual Inhibitors Targeting Cyclin-Dependent Kinase and Histone Deacetylase for Treating Cancer [published online ahead of print, 2021 Oct 8]. J Med Chem. 2021;10.1021/acs.jmedchem.1c01311. [Content Brief]

Kinase Assay ^[1]	GSK-3β is expressed in and purified from insect Sf9 cells. It is assayed, following a 1/100 dilution in 1 mg/mL BSA, 10 mM DTT, with 5 μL of 40 μM GS-1 peptide as a substrate, in buffer A, in the presence of 15 μM[γ-³²P]ATP (3000 Ci/mmol; 1 mCi/mL) in a final volume of 30 μL. After 30-min incubation at 30°C, 25-μL aliquots of supernatant are spotted onto 2.5×3-cm pieces of Whatman P81 phosphocellulose paper, and, 20 s later, the filters are washed five times (for at least 5 min each time) in a solution of 10 mL of phosphoric acid/liter of water. The wet filters are counted in the presence of 1 mL of ACS scintillation fluid^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Assay ^[3]	Cytotoxicity of Indirubin-3'-monoxime in monocytes is analysed by MTT assay in a 96-well format using a multi-well scanning spectrophotometer. Neutrophils (5×10⁶ cells/mL) or monocytes (2×10⁶ cells/mL) are incubated for 30 min with Indirubin-3'-monoxime, and the viability of the cells is analysed by MTT assay. Compared with vehicle (0.3% DMSO), no significant acute cytotoxicity is observed (neutrophils: 103.9±4.4%; monocytes: 129.4±5.4%; n=3, each)^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[2]	Male mice (5-6 weeks old) are randomLy assigned into five groups (n=10). Group 1: receive normal pellet diet (NPD); Group 2: receive a HFD; Group 3-5 receive HFD for 8 weeks followed by Indirubin-3'-monoxime treatment (0.1, 0.2 and 0.4 mg/kg i.p, respectively) once daily for 1 week. Indirubin-3'-monoxime is dissolved in (2.5% v/v) DMSO in saline. The mice in NPD and HFD groups receive an equivalent volume of vehicle (2.5% v/v DMSO in saline). Doses of Indirubin-3'-monoxime are selected. Mice are kept under standard husbandry conditions (22±1°C and 60% humidity) and maintained on a 12/12-h light/dark schedule with free access to food and water for 8 weeks. Body weight is recorded weekly throughout the experimental period^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Leclerc S, et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem. 2001 Jan 5;276(1):251-60. [Content Brief] [2]. Sharma S, et al. Neuroprotective role of Indirubin-3'-monoxime, a GSKβ inhibitor in high fat diet induced cognitive impairment in mice. Biochem Biophys Res Commun. 2014 Oct 3;452(4):1009-15. [Content Brief] [3]. Blazevic T, et al. Indirubin-3'-monoxime exerts a dual mode of inhibition towards leukotriene-mediated vascular smooth muscle cell migration. Cardiovasc Res. 2014 Mar 1;101(3):522-32. [Content Brief] [4]. Cao Z, et al. Indirubin Derivatives as Dual Inhibitors Targeting Cyclin-Dependent Kinase and Histone Deacetylase for Treating Cancer [published online ahead of print, 2021 Oct 8]. J Med Chem. 2021;10.1021/acs.jmedchem.1c01311. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.6065 mL	18.0323 mL	36.0646 mL	90.1616 mL
	5 mM	0.7213 mL	3.6065 mL	7.2129 mL	18.0323 mL
	10 mM	0.3606 mL	1.8032 mL	3.6065 mL	9.0162 mL
	15 mM	0.2404 mL	1.2022 mL	2.4043 mL	6.0108 mL
	20 mM	0.1803 mL	0.9016 mL	1.8032 mL	4.5081 mL
	25 mM	0.1443 mL	0.7213 mL	1.4426 mL	3.6065 mL
	30 mM	0.1202 mL	0.6011 mL	1.2022 mL	3.0054 mL
	40 mM	0.0902 mL	0.4508 mL	0.9016 mL	2.2540 mL
	50 mM	0.0721 mL	0.3606 mL	0.7213 mL	1.8032 mL
	60 mM	0.0601 mL	0.3005 mL	0.6011 mL	1.5027 mL
	80 mM	0.0451 mL	0.2254 mL	0.4508 mL	1.1270 mL
	100 mM	0.0361 mL	0.1803 mL	0.3606 mL	0.9016 mL

Indirubin-3'-monoxime Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Indirubin-3'-monoxime160807-49-8Indirubin-3'-oximeGSK-3CDKLipoxygenaseGlycogen synthase kinase-3Glycogen synthase kinase 3Cyclin dependent kinaseLOXInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Indirubin-3'-monoxime (Synonyms: Indirubin-3'-oxime)

Customer Review

Other Forms of Indirubin-3'-monoxime:

Indirubin-3'-monoxime Related Antibodies

3 Publications Citing Use of MCE Indirubin-3'-monoxime

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All GSK-3 Isoform Specific Products:

View All CDK Isoform Specific Products:

View All Lipoxygenase Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Indirubin-3'-monoxime Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Indirubin-3'-monoxime Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report